IL-2 receptor

The interleukin-2 receptor (IL-2R) is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that binds and responds to a cytokine called IL-2.

Composition

IL-2 binds to the IL-2 receptor, which has three forms, generated by different combinations of three different proteins, often referred to as "chains": α (alpha) (also called IL-2Rα, CD25, or Tac antigen), β (beta) (also called IL-2Rβ, or CD122), and γ (gamma) (also called IL-2Rγ, γc, common gamma chain, or CD132); these subunits are also parts of receptors for other cytokines. The β and γ chains of the IL-2R are members of the type I cytokine receptor family.

Structure-activity relationships of the IL-2/IL-2R interaction

The three receptor chains are expressed separately and differently on various cell types and can assemble in different combinations and orders to generate low, intermediate, and high affinity IL-2 receptors.

The α chain binds IL-2 with low affinity, the combination of β and γ together form a complex that binds IL-2 with intermediate affinity, primarily on memory T cells and NK cells; and all three receptor chains form a complex that binds IL-2 with high affinity (Kd ~ 10−11 M) on activated T cells and regulatory T cells The intermediate and high affinity receptor forms are functional and cause changes in the cell when IL-2 binds to them.

Ilyushin Il-2

The Ilyushin Il-2 (Cyrillic: Илью́шин Ил-2) Sturmovik was a ground-attack aircraft (Cyrillic: Штурмови́к, Šturmovík) produced by the Soviet Union in large numbers during the Second World War. With 36,183 examples of the Il-2 produced during the war, and in combination with its successor, the Ilyushin Il-10, a total of 42,330 were built, making it the single most produced military aircraft design in aviation history, as well as one of the most produced piloted aircraft in history along with the American postwar civilian Cessna 172 and the Soviet Union's own then-contemporary Polikarpov Po-2 Kukuruznik multipurpose biplane, itself sometimes seen side-by-side with the big armored Ilyushin monoplane on the front lines.

To Il-2 pilots, the aircraft was simply the diminutive "Ilyusha". To the soldiers on the ground, it was the "Hunchback", the "Flying Tank" or the "Flying Infantryman". Its postwar NATO reporting name was "Bark". The Il-2 aircraft played a crucial role on the Eastern Front. Joseph Stalin paid the Il-2 a great tribute in his own inimitable manner: when a particular production factory fell behind on its deliveries, Stalin sent an angrily worded cable to the factory manager, stating "They are as essential to the Red Army as air and bread." "I demand more machines. This is my final warning!"

IL-2

IL2 or IL-2 may refer to:

  • Ilyushin Il-2 Shturmovik, a World War II era Soviet ground attack aircraft
  • IL-2 Sturmovik (video game series), a series of games named after the Ilyushin Il-2 aircraft
  • IL-2 Sturmovik (video game), a 2001 video game, the first in the series
  • IL-2 Sturmovik: Forgotten Battles, a 2003 sequel to the IL-2 Sturmovik video game
  • IL-2 Sturmovik: 1946, a 2006 expansion pack for the IL-2 Sturmovik video game
  • IL-2 Sturmovik: Birds of Prey, a 2009 sequel to the IL-2 Sturmovik video game
  • IL-2 Sturmovik: Cliffs of Dover, a 2011 sequel to the original IL-2 Sturmovik video game
  • IL-2 Sturmovik: Battle of Stalingrad, a 2013 sequel to the original IL-2 Sturmovik video game
  • Interleukin 2, a cytokine glycoprotein that stimulates the growth of T cell lymphocytes and provides other biochemical signaling to the immune system
  • IL-2 receptor, a protein that binds and responds to interleukin 2
  • Illinois' 2nd congressional district
  • Illinois Route 2, a north–south state road in northern Illinois
  • Podcasts:

    PLAYLIST TIME:

    Latest News for: il-2 receptor

    Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

    ACCESSWIRE 18 Mar 2025
    Icotrokinra (JNJ-2113), the first-ever oral IL-23 receptor antagonist developed in collaboration with Johnson & Johnson, which has shown substantial efficacy in multiple Phase 3 trials for psoriasis ...

    Ankylosing spondylitis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Kinevant Sciences, MoonLake ...

    GetNews 17 Mar 2025
    ... that inhibits both IL-17A and IL-17F ... With best-in-class potential, NEU-111 reduces signaling through multiple cytokine receptors, including those for interleukin (IL)-12, IL-23, and interferon (IFN).

    Atopic Dermatitis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ...

    GetNews 14 Mar 2025
    ... IL-13 Inhibitors, leukotriene inhibitors, Kappa opioid receptor (KOR) agonist, NK-1 receptor antagonist, and others in the upcoming market of Atopic Dermatitis and pruritus in Atopic Dermatitis.

    Bullous Pemphigoid Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, ...

    GetNews 12 Mar 2025
    Bullous Pemphigoid Drugs Uptake FASENRA (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils ... DUPIXENT (dupilumab) is a monoclonal antibody targeting the chain of the interleukin (IL)-4 receptor.

    Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to ...

    ACCESSWIRE 10 Mar 2025
    Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor,iv which underpins the inflammatory response in moderate-to-severe plaque psoriasis, ...

    Pruritus Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approvals, Medication, Prevalence, MOA, ...

    GetNews 10 Mar 2025
    "Pruritus Treatment Market" ... Pruritus Overview ... The development of novel therapies, including NK-1 receptor antagonists, IL-31 inhibitors, and JAK inhibitors, has expanded treatment options beyond traditional antihistamines and corticosteroids ... @ ... 1 ... 2 ... 3.

    Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New ...

    ACCESSWIRE 08 Mar 2025
    Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor.xviThe IL-23 pathway underpins the inflammatory response in moderate-to-severe plaque ...

    Vulvar Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

    GetNews 06 Mar 2025
    This innovative drug aims to enhance anti-tumor immunity by targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and preferentially binding to the IL-2 receptor beta subunit (IL-2Rβ).

    Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

    Pharmiweb 04 Mar 2025
    Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to JNJ Innovative Medicines (“JNJ”), formerly Janssen Biotech, Inc.

    A Rare White Blood Cell Boosts Cancer-Fighting Immune Cells

    The Scientist 03 Mar 2025
    Treating the tumor-bearing mice with IL-3 reduced tumor growth and metastasis ... Using flow cytometry, they isolated splenocyte populations and observed that basophils expressed high levels of IL-3 receptors.

    Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)

    Pharmiweb 03 Mar 2025
    Depemokimab, a monoclonal antibody that targets IL-5, is the ... Targeting the IL-5 pathway ... Human airway epithelial cells express a functional IL-5 receptor ... IL-5 receptor expression in lung fibroblasts.
    • 1
    ×